Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Rosiglitazone: what went wrong?
Home
Publications
Rosiglitazone: what went wrong?
Rosiglitazone: what went wrong?
Author:
DC
Deborah Cohen
Deborah Cohen
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Publisher website
Google Scholar
6 September 2010
journal article
Published by
BMJ
in
BMJ
Vol. 341
(sep06 2)
,
c4848
DOI:
10.1136/bmj.c4848
PMID:
20819889
Abstract
Over 10 years after the diabetes drug rosiglitazone was approved by regulators, and despite studies on tens of thousands of people, questions remain about its cardiovascular safety. An investigation by the
BMJ
looks at why this happened.
Keywords
WRONG
BMJ
ROSIGLITAZONE
QUESTIONS REMAIN
CARDIOVASCULAR SAFETY
DRUG ROSIGLITAZONE
YEARS
REGULATORS
PEOPLE
QUESTIONS
Related articles
Cited
Cited by 100 articles
Scroll to top